Navigation Links
Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
Date:10/10/2007

ARLINGTON HEIGHTS, Ill., Oct. 10 /PRNewswire-USNewswire/ -- Face transplants, once on the fringe of medicine, may eventually become more mainstream because of new estimates that suggest the risk of tissue rejection might be lower than previously thought, according to a recent review in Plastic and Reconstructive Surgery(R) (PRS), the official medical journal of the American Society of Plastic Surgeons (ASPS).

"We can only know the true immunological risks associated with face transplants by carefully observing those who have already had the procedure," said ASPS President Roxanne Guy, MD. "While this paper doesn't provide conclusive evidence of the immunological risks, it will help us move forward in making face transplants part of mainstream medicine."

Currently, immunosuppressive drugs are the biggest barrier the medical community faces in performing any transplant because the potential long-term side effects of these medications can make the risk too great.

The authors suggest previous immunological risk projections are inaccurate because they were based on immunosuppression drug regimes that are different than the regimes that will be required of face transplant patients.

When utilizing an immunosuppressive drug regimen consistent with face transplant recipient requirements, the authors believe patients would have a relatively low risk of chronic or continual rejection after surgery -- less than 10 percent. In addition, advances in immunosuppression therapies have increased the capacity to manage face transplant patients and potentially reduce acute or immediate rejection episodes.

The authors also suggest that the immunological risks are lower because face transplant patients may on average be healthier and less likely to suffer from extenuating health issues. Organ transplant recipients, on the other hand, often are extremely sick and have numerous, pre-existing health conditions that make them more susceptible to the complications related to immunosuppressive treatment. For example, kidney transplant recipients commonly have hypertension, diabetes, anemia or bone disease. Face transplant recipients; however, may not be hindered by additional health concerns, lowering their risk.

Additionally, the human hand is comprised of similar tissue as the face. This has led plastic surgeons to hypothesize that face transplant patients would carry similar low risk of acute rejection as hand transplant recipients.

Visit http://www.plasticsurgery.org for referrals to ASPS Member Surgeons and to learn more about cosmetic and reconstructive plastic surgery.

The American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world. With more than 6,000 members, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises 90 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.


'/>"/>
SOURCE American Society of Plastic Surgeons
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
3. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
4. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
5. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
6. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
7. Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the Annual Meeting of the Associated Professional Sleep Societies
8. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
9. Clinical Trial Results Suggest Long-Term Treatment Benefit of Tetrabenazine for Chorea Associated with Huntingtons Disease
10. Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions
11. Insmed Releases Positive Results from Iplex Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 9, 2016 On Tuesday, February ... met with its Arthritis Advisory Committee to ... Johnson & Johnson,s Remicade and most likely ... the U.S. The Biologics Prescribers Collaborative (BPC) ... Alliance for Patient Access, American Association of ...
(Date:2/10/2016)... February 10, 2016 The campaign aims ... 5 years reach the milestone of their 5 th ... ensure 2,50,532 children between the ages of 2 - 5 ... --> The campaign aims to ... reach the milestone of their 5 th birthday   ...
(Date:2/9/2016)... FARMINGDALE, N.Y., Feb. 9, 2016  Misonix, Inc. ... company that designs, manufactures and markets innovative therapeutic ... wound debridement, cosmetic surgery, laparoscopic surgery and other ... second quarter and the first half of fiscal ... --> --> Highlights ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Ongoing news ... Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer look ... released today illustrates the prevalence and causes of TBI among the aging population, and ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading ... the fourth quarter and full year ended December 31, 2015 on Monday, February 29, ... webcast for the investment community following the release at 4:30 PM ET. Investors interested ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The Association ... inspirational speaker Jan Fox will serve as keynote speaker at the organization’s 2016 ... with tools to more effectively communicate with their own organizational staff and leadership. ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , ... with Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp ... publication date is March 16, 2016. A free review copy is available to ...
Breaking Medicine News(10 mins):